He is a seasoned professional having worked in reputed corporates in API business with over 35+ years of experience covering manufacturing, general management, and business
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
WuXi STA opens a new large scale continuous manufacturing plant
Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
The company already has the world’s largest capacity for ibuprofen and is now looking at expansion in new molecules as the idea is to actually de-risk the business
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Subscribe To Our Newsletter & Stay Updated
